Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Kraig Biocraft Laboratories (KBLB) Cash & Equivalents (2016 - 2022)

Kraig Biocraft Laboratories (KBLB) has disclosed Cash & Equivalents for 10 consecutive years, with $4.3 million as the latest value for Q3 2022.

  • Quarterly Cash & Equivalents rose 60.54% to $4.3 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Sep 2022, up 60.54% year-over-year, with the annual reading at $2.4 million for FY2021, N/A changed from the prior year.
  • Cash & Equivalents hit $4.3 million in Q3 2022 for Kraig Biocraft Laboratories, down from $4.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $4.8 million in Q2 2022 to a low of $13697.0 in Q4 2018.
  • Historically, Cash & Equivalents has averaged $1.9 million across 4 years, with a median of $927038.0 in 2021.
  • Biggest five-year swings in Cash & Equivalents: crashed 69.98% in 2018 and later surged 1857.97% in 2019.
  • Year by year, Cash & Equivalents stood at $13697.0 in 2018, then soared by 1967.23% to $283148.0 in 2019, then skyrocketed by 731.74% to $2.4 million in 2021, then soared by 83.62% to $4.3 million in 2022.
  • Business Quant data shows Cash & Equivalents for KBLB at $4.3 million in Q3 2022, $4.8 million in Q2 2022, and $3.9 million in Q1 2022.